Castle Biosciences Inc. (CSTL) Tops Q2 EPS by 58c, Beats on Revenue; Offers FY24 Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts CSTL Hot Sheet
Join SI Premium – FREE
Castle Biosciences Inc. (NASDAQ: CSTL) reported Q2 EPS of $0.31, $0.58 better than the analyst estimate of ($0.27). Revenue for the quarter came in at $87 million versus the consensus estimate of $69.37 million.
GUIDANCE:
Castle Biosciences Inc. sees FY2024 revenue of $275-300 million, versus the consensus of $260.4 million.
For earnings history and earnings-related data on Castle Biosciences Inc. (CSTL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- MFA Financial (MFA) Misses Q3 EPS by 2c
- Avnet (AVT) Tops Q1 EPS by 97c ; Offers Guidance
- Marriott Vacations Worldwide (VAC) Tops Q3 EPS by 7c; offers guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
